[go: up one dir, main page]

WO2022112513A3 - Nanoparticules comprenant des particules d'oxyde de fer incorporées dans des micelles polymères - Google Patents

Nanoparticules comprenant des particules d'oxyde de fer incorporées dans des micelles polymères Download PDF

Info

Publication number
WO2022112513A3
WO2022112513A3 PCT/EP2021/083200 EP2021083200W WO2022112513A3 WO 2022112513 A3 WO2022112513 A3 WO 2022112513A3 EP 2021083200 W EP2021083200 W EP 2021083200W WO 2022112513 A3 WO2022112513 A3 WO 2022112513A3
Authority
WO
WIPO (PCT)
Prior art keywords
core
iron oxide
nanoparticles
oxide particles
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/083200
Other languages
English (en)
Other versions
WO2022112513A2 (fr
Inventor
Natalie HORVAT
Martina U. MUCKENTHALER
Matthias W. Hentze
Tobias A. BAUER
Matthias BARZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Europaisches Laboratorium fuer Molekularbiologie EMBL
Universitaet Heidelberg
Original Assignee
Europaisches Laboratorium fuer Molekularbiologie EMBL
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaisches Laboratorium fuer Molekularbiologie EMBL, Universitaet Heidelberg filed Critical Europaisches Laboratorium fuer Molekularbiologie EMBL
Publication of WO2022112513A2 publication Critical patent/WO2022112513A2/fr
Publication of WO2022112513A3 publication Critical patent/WO2022112513A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une particule coeur-écorce comprenant une micelle polymère réticulée à coeur (CCPM), et au moins une nanoparticule d'oxyde de fer (ION), l'au moins une ION étant située dans le coeur de la CCPM. L'invention concerne en outre des procédés de production de la particule coeur-écorce, des compositions les comprenant, la particule coeur-écorce ou la composition destinée à être utilisée en médecine, et des procédés de modulation de l'activité de cellules immunitaires et des procédés dpour traiter un dérèglement du système immunitaire, le cancer, l'anémie et des lésions nerveuses.
PCT/EP2021/083200 2020-11-27 2021-11-26 Nanoparticules comprenant des particules d'oxyde de fer incorporées dans des micelles polymères Ceased WO2022112513A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210176.2 2020-11-27
EP20210176 2020-11-27

Publications (2)

Publication Number Publication Date
WO2022112513A2 WO2022112513A2 (fr) 2022-06-02
WO2022112513A3 true WO2022112513A3 (fr) 2022-07-21

Family

ID=73642581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/083200 Ceased WO2022112513A2 (fr) 2020-11-27 2021-11-26 Nanoparticules comprenant des particules d'oxyde de fer incorporées dans des micelles polymères

Country Status (1)

Country Link
WO (1) WO2022112513A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115154482B (zh) * 2022-01-14 2023-05-02 河北金益合生物技术有限公司 硫化铁纳米酶抗人乳头瘤病毒的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040513A1 (fr) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions et procédés d'administration de bêta-lapachone
KR20130054676A (ko) * 2011-11-17 2013-05-27 재단법인대구경북과학기술원 약물 전달을 위한 코어 크로스링킹된 고분자 마이셀 조성물 및 이의 제조방법
US20130195755A1 (en) * 2010-06-28 2013-08-01 Centrum Fur Angewandte Nanotechnologie (Can) Gmbh Micellular combination comprising a nanoparticle and a plurality of surfmer ligands
WO2020227620A1 (fr) * 2019-05-08 2020-11-12 Board Of Regents, The University Of Texas System Peptides thérapeutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942348B1 (fr) 2014-05-07 2017-10-25 Johannes Gutenberg-Universität Mainz Dérivés d'acides aminés protégés par du thiol et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195755A1 (en) * 2010-06-28 2013-08-01 Centrum Fur Angewandte Nanotechnologie (Can) Gmbh Micellular combination comprising a nanoparticle and a plurality of surfmer ligands
WO2012040513A1 (fr) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions et procédés d'administration de bêta-lapachone
KR20130054676A (ko) * 2011-11-17 2013-05-27 재단법인대구경북과학기술원 약물 전달을 위한 코어 크로스링킹된 고분자 마이셀 조성물 및 이의 제조방법
WO2020227620A1 (fr) * 2019-05-08 2020-11-12 Board Of Regents, The University Of Texas System Peptides thérapeutiques

Also Published As

Publication number Publication date
WO2022112513A2 (fr) 2022-06-02

Similar Documents

Publication Publication Date Title
Qi et al. Graphene oxide-based magnetic nanocomposites for the delivery of melittin to cervical cancer HeLa cells
WO2022112513A3 (fr) Nanoparticules comprenant des particules d'oxyde de fer incorporées dans des micelles polymères
US11419826B2 (en) Surface-modified mesoporous silica nanoparticle for blood-brain barrier penetration,tumor targeting and cancer metastasis treatment, methods of production and uses thereof
NZ768232A (en) Implantable particles and related methods
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
IL195328A0 (en) Antibodies binding to anionic phospholipids and aminophospholipids and their use in the preparation of pharmaceutical compositions for treating viral infections
WO2021092464A3 (fr) Oligonucléotides chimiquement modifiés ciblant la protéine à bromodomaine 4 (brd4) pour immunothérapie
WO2022072293A3 (fr) Méthodes et compositions pour l'imprégnation et la rétention synergiques de ligands à petites molécules
MX2021011824A (es) Composiciones, dispositivos y metodos para la terapia del factor vii.
WO2023077038A3 (fr) Systèmes et méthodes pour identifier des antigènes associés au cmh pour une intervention thérapeutique
CN100462092C (zh) 一种外用中药及其制备方法
MX2024002100A (es) Partículas coloidales modificadas para uso en el tratamiento de la hemofilia a.
KR20130047555A (ko) 자외선 차단용 유무기 복합분체 및 이를 함유하는 화장료 조성물
WO2014047292A3 (fr) Compositions de polyélectrolytes bioactifs à partir de matières organiques humidifiées et utilisations associées
WO2024131348A9 (fr) Nanosuspension à large spectre contenant de la pyraclostrobine pour prévenir et traiter des maladies fongiques
WO2022241331A3 (fr) Nanoparticules hybrides polymères-lipides d'emricasan et leur utilisation
WO2024220446A3 (fr) Préparations cellulaires modifiées pour le traitement de l'hémophilie
CN114392201B (zh) 一种软膜粉
KR102132551B1 (ko) 바이오 셀룰로오스 마스크팩의 제조방법
KR20140095736A (ko) 근적외선 차단용 복합분체
JP2023118050A (ja) 脳癌又は脳転移の予防及び治療のための薬物負荷型メソ多孔質シリカナノ粒子
EP4545066A3 (fr) Derives de 4-phenyl-tetrahydropyridine pour le traitement de maladies auditives
KR102316588B1 (ko) 화장료 조성물의 제조 방법
CN105250162A (zh) 一种防红血丝抗龟裂粉底液
KR101442203B1 (ko) 다기능 복합캡슐 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21824494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21824494

Country of ref document: EP

Kind code of ref document: A2